1. Home
  2. INCY vs EMA Comparison

INCY vs EMA Comparison

Compare INCY & EMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INCY
  • EMA
  • Stock Information
  • Founded
  • INCY 1991
  • EMA 1998
  • Country
  • INCY United States
  • EMA Canada
  • Employees
  • INCY N/A
  • EMA N/A
  • Industry
  • INCY Biotechnology: Commercial Physical & Biological Resarch
  • EMA Electric Utilities: Central
  • Sector
  • INCY Health Care
  • EMA Utilities
  • Exchange
  • INCY Nasdaq
  • EMA Nasdaq
  • Market Cap
  • INCY 17.0B
  • EMA 14.3B
  • IPO Year
  • INCY 1993
  • EMA N/A
  • Fundamental
  • Price
  • INCY $105.96
  • EMA $48.17
  • Analyst Decision
  • INCY Buy
  • EMA
  • Analyst Count
  • INCY 19
  • EMA 0
  • Target Price
  • INCY $89.19
  • EMA N/A
  • AVG Volume (30 Days)
  • INCY 2.9M
  • EMA 142.9K
  • Earning Date
  • INCY 10-28-2025
  • EMA 11-07-2025
  • Dividend Yield
  • INCY N/A
  • EMA 4.34%
  • EPS Growth
  • INCY 3878.02
  • EMA 67.89
  • EPS
  • INCY 5.90
  • EMA 2.65
  • Revenue
  • INCY $4,813,105,000.00
  • EMA $6,126,111,896.00
  • Revenue This Year
  • INCY $19.33
  • EMA $22.22
  • Revenue Next Year
  • INCY $10.47
  • EMA N/A
  • P/E Ratio
  • INCY $18.34
  • EMA $18.04
  • Revenue Growth
  • INCY 18.09
  • EMA 15.17
  • 52 Week Low
  • INCY $53.56
  • EMA $43.90
  • 52 Week High
  • INCY $109.28
  • EMA $49.77
  • Technical
  • Relative Strength Index (RSI)
  • INCY 73.65
  • EMA 50.26
  • Support Level
  • INCY $91.16
  • EMA $46.94
  • Resistance Level
  • INCY $109.28
  • EMA $48.90
  • Average True Range (ATR)
  • INCY 4.54
  • EMA 0.60
  • MACD
  • INCY 0.92
  • EMA -0.09
  • Stochastic Oscillator
  • INCY 86.44
  • EMA 47.38

About INCY Incyte Corp.

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

About EMA Emera Incorporated Common Shares

Emera is a geographically diverse energy and services company investing in electricity generation, transmission, and distribution as well as gas transmission and utility energy services. Emera has operations throughout North America and the Caribbean countries.

Share on Social Networks: